SCHEMBL16309346

SCHEMBL16309346

C=NC(=O)c1ccc2ccccc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.67
CES1 P23141 1/20 0.67
SMN1; SMN2 Q16637 3/20 0.56
KDM4E B2RXH2 3/20 0.56
HPGD P15428 2/20 0.56
ALDH1A1 P00352 2/20 0.56
MEN1 O00255 1/20 0.56
EGFR P00533 1/20 0.56
TP53 P04637 1/20 0.56
CYP3A4 P08684 1/20 0.56
MAPT P10636 1/20 0.56
PKM P14618 1/20 0.56
ALOX15 P16050 1/20 0.56
ALOX12 P18054 1/20 0.56
JAK1 P23458 1/20 0.56
MAPK1 P28482 1/20 0.56
KMT2A Q03164 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
PTPN1 P18031 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14394377 0.82 CES2 (0.63) CES2CES1SMN1; SMN2KDM4EHPGD
SCHEMBL17573111 0.81 CES2 (0.43) CES2CES1SMN1; SMN2KDM4EALDH1A1
SCHEMBL7220072 0.81 CES2 (1.00) CES2CES1SMN1; SMN2KDM4EHPGD
SCHEMBL31032483 0.81 CES2 (1.00) CES2CES1SMN1; SMN2KDM4EHPGD
SCHEMBL8009171 0.78 CES2 (0.59) CES2CES1SMN1; SMN2KDM4EHPGD
SCHEMBL14504180 0.77 SLC9A1 (0.62) CES2CES1KDM4EF2PLG
SCHEMBL8009663 0.77 CES2 (0.57) CES2CES1SMN1; SMN2KDM4EHPGD
SCHEMBL9160200 0.77 CES2 (0.57) CES2CES1SMN1; SMN2KDM4EHPGD
SCHEMBL8344284 0.77 CES2 (0.68) CES2CES1SMN1; SMN2KDM4EHPGD
SCHEMBL64121 0.77 CES2 (0.68) CES2CES1SMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980908-B2 Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation VIRGINIA COMMONWEALTH UNIVERSITY (US) 2015-03-17 US disclosed
US-20140371255-A1 NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS AND THEIR USE IN TREATING OPIOID ADDICTION AND OPIOID INDUCED CONSTIPATION VIRGINIA COMMONWEALTH UNIVERSITY (US) 2014-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371255-A1 NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS AND THEIR USE IN TREATING OPIOID ADDICTION AND OPIOID INDUCED CONSTIPATION OPRM1, OPRK1, OPRL1 CES2 878/4885CES1 1840/4885SMN1; SMN2 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.